Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is currently focused on the development and advancement of cutting-edge, one-time gene therapies for neurodegenerative diseases and has a strong pipeline, including the promising PBFT02 asset. While the company faces some regulatory hurdles, it has a strong cash position and has adjusted its penetration assumptions and launch timelines in a conservative manner, resulting in a new price target of $23.

Bears say

Passage Bio is facing regulatory uncertainties with their PBFT02 gene therapy for FTD-GRN and potential setbacks in clinical trial design. Their current cash balance of $46.3M may provide a runway into 1Q27, but the lack of flexibility from the FDA and potential reduction in OpEx could create challenges for the company. While there is potential for positive biomarker data and regulatory feedback in the coming quarters, the negative outlook and high-risk nature of the biotech industry may not make this stock an attractive investment opportunity.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.